News Sentiment

ESPR sentiment intelligence

Esperion Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 3.18 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.6% over one week, +1.0% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 0.6% Price digesting
Trend fit Trend inactive 1.0% over four weeks
Fair value 45.2% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 30
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
TradingView 8
www.marketscreener.com 4
Stocktwits 3
GlobeNewswire 3
simplywall.st 3
Moomoo 2
Market source 2

Event Lens

What the news is about

Classified themes
Market update 24
Deals and strategy 13
Earnings 6
Analyst action 4
Balance sheet 1
Guidance 1
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Stock Titan Direct company coverage

Wasatch Advisors reports 0.7% Esperion Therapeutics (ESPR) stake

Wasatch Advisors has reported a 0.7% beneficial ownership stake in Esperion Therapeutics (ESPR), amounting to 1,930,185 shares. This filing, a Schedule 13G/A, indicates that Wasatch Advisors holds sole voting and dispositive power over these shares, qualifying it as an "Ownership

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 21:16
Source
Stock Titan
TradingView Direct company coverage

Enterprise value to revenue forward of Esperion Therapeutics, Inc. – DUS:0ET

This article provides financial information for Esperion Therapeutics, Inc. (DUS:0ET) on TradingView, focusing specifically on its enterprise value to revenue forward metric. The content highlights a specific financial period, value, and change for the company, accessible through

Tone
Neutral 50/100
Event
Earnings
Published
14 Jul 2026 09:11
Source
TradingView
TradingView Direct company coverage

PFE6265887 Bond Risk Profile

This page provides a risk profile for the Esperion Therapeutics, Inc. bond (PFE6265887) with a 5.75% coupon maturing on June 15, 2030. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help users evaluate t

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 03:11
Source
TradingView
Investing.com Nigeria Direct company coverage

Form 4 Esperion Therapeutics Inc For: 13 July By Investing.com

This article announces the filing of Form 4 for Esperion Therapeutics Inc., dated July 13. Form 4 is a document filed with the SEC by company insiders detailing changes in their ownership of the company's stock. The article mentions the stock symbol ESPR and its slight price chan

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 22:11
Source
Investing.com Nigeria
TradingView Direct company coverage

PFE6265887 Bond Profile — Key Metrics

This article provides key metrics for the Esperion Therapeutics, Inc. bond PFE6265887, which has a 5.75% coupon rate and matures on June 15, 2030. The bond has an outstanding amount of $100 million and a face value of $1,000. Esperion Therapeutics is a biopharmaceutical company f

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:12
Source
TradingView
Stock Titan Direct company coverage

Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs in merger

Esperion Therapeutics director Seth H. Z. Fischer cashed out his equity holdings in the company as part of a merger where Esperion became a wholly-owned subsidiary of Essence Parent Inc. He disposed of 141,023 common shares, 79,873 restricted stock units, and several in-the-money

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 20:12
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity

Esperion Therapeutics' CFO Benjamin Halladay disposed of his equity, including 705,410 shares of common stock and various stock options, due to the company's merger with Essence Parent Inc. The merger converted each share of common stock and in-the-money options into $3.16 cash p

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 20:12
Source
Stock Titan
Stock Titan Direct company coverage

Esperion Therapeutics (ESPR) director converts shares and options into $3.16 cash and CVRs

Esperion Therapeutics director Jay Shepard reported dispositions of shares and stock options following the closing of a merger with Essence Parent Inc. and Essence MergerCo Inc. His 164,472 common shares were converted into $3.16 cash per share plus one contingent value right (CV

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

Esperion Therapeutics (ESPR) director equity cashed out at $3.16 plus CVRs

Esperion Therapeutics director Robert E. Hoffman reported the disposition of common stock and stock options due to the company's merger, where it became a wholly owned subsidiary of Essence Parent Inc. His 85,153 shares were converted into $3.16 cash per share plus one

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

[POSASR] Esperion Therapeutics, Inc. SEC Filing

Esperion Therapeutics, Inc. has filed a Post-Effective Amendment No. 1 to its Form S-3ASR registration statement (No. 333-258397) to deregister unsold securities. This action follows the company's merger with Essence MergerCo Inc., a wholly-owned subsidiary of Essence Parent Inc.

Tone
Neutral 50/100
Event
Deals and strategy
Published
13 Jul 2026 16:12
Source
Stock Titan
Stock Titan Direct company coverage

[POS AM] Esperion Therapeutics, Inc. SEC Filing

Esperion Therapeutics, Inc. has filed a post-effective amendment to several S-3 and S-3MEF registration statements to deregister unsold securities. This action follows the company's merger with MergerCo, a wholly-owned subsidiary of Essence Parent Inc., which became effective on

Tone
Negative 19/100
Event
Deals and strategy
Published
13 Jul 2026 16:12
Source
Stock Titan
TradingView Direct company coverage

Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing

Esperion Therapeutics (ESPR) announced its decision to delist its common stock from Nasdaq following a merger. The company has requested Nasdaq to file a Form 25 for delisting and deregistration and plans to file a Form 15 to suspend its SEC reporting obligations.

Tone
Negative 5/100
Event
Deals and strategy
Published
13 Jul 2026 13:41
Source
TradingView
Stock Titan Direct company coverage

Esperion Therapeutics (ESPR) moves to remove its Nasdaq listing

Esperion Therapeutics, Inc. (ESPR) is removing its common stock from listing and registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934. This delisting was certified by Nasdaq and affects the company's common stock, meaning less vis

Tone
Negative 29/100
Event
Market update
Published
13 Jul 2026 13:41
Source
Stock Titan
www.marketscreener.com Direct company coverage

Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Value-Dynamic Index

Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been dropped from the Russell 2000 Value-Dynamic Index. This article also details the company's profile as a commercial-stage biopharmaceutical company focused on cardiometabolic and rare/orphan disease therapies, including its prod

Tone
Negative 30/100
Event
Market update
Published
10 Jul 2026 15:41
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 3000 Value Benchmark

Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell 3000 Value Benchmark, alongside several other Russell indices. The biopharmaceutical company specializes in developing cardiometabolic and rare/orphan disease therapies, including medications like NEXLE

Tone
Negative 30/100
Event
Market update
Published
10 Jul 2026 15:39
Source
www.marketscreener.com
TradingView Direct company coverage

Esperion Therapeutics Clears Key Hurdle as Stockholders Approve Essence Merger

Esperion Therapeutics' stockholders have approved the company's merger agreement with Essence Parent and Essence MergerCo in a virtual meeting held on July 8, 2026. The approval means Essence MergerCo will merge with Esperion, with Esperion becoming a wholly-owned subsidiary of E

Tone
Positive 76/100
Event
Deals and strategy
Published
10 Jul 2026 15:09
Source
TradingView
www.marketscreener.com Direct company coverage

Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell Small Cap Comp Value Index

Esperion Therapeutics, Inc. (NasdaqGM:ESPR) has been removed from the Russell Small Cap Comp Value Index, as well as several other Russell indices including the Russell 2000 Growth, Russell 2500 Growth, and Russell 3000 indices. The company is a biopharmaceutical firm focused on

Tone
Negative 30/100
Event
Market update
Published
10 Jul 2026 03:40
Source
www.marketscreener.com
www.marketscreener.com Direct company coverage

Esperion Therapeutics, Inc.(NasdaqGM:ESPR) dropped from Russell 2000 Growth Benchmark

Esperion Therapeutics Inc. (NasdaqGM:ESPR) has been removed from several Russell Growth and Value benchmarks, including the Russell 2000 Growth Benchmark. This move affects the company's inclusion in various small-cap and broader Russell indices. Esperion Therapeutics is a biopha

Tone
Negative 20/100
Event
Market update
Published
10 Jul 2026 03:10
Source
www.marketscreener.com
Stock Titan Direct company coverage

Esperion Therapeutics (ESPR) investors back merger with Essence Parent in special meeting vote

Esperion Therapeutics (ESPR) stockholders have approved the merger with Essence Parent Inc. at a special meeting held on July 8, 2026. This approval, with 135,326,793 votes in favor, moves forward the transaction for Esperion to become a wholly owned subsidiary of Essence Parent.

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 12:39
Source
Stock Titan
AD HOC NEWS Direct company coverage

Esperion Therapeutics stock leans on its cholesterol portfolio.

Esperion Therapeutics, a Nasdaq-listed company, is judged by the market on the performance of its cholesterol-lowering medicines, commercial execution, and prescription trends. The company's core business focuses on non-statin LDL-C lowering therapies, Nexletol and Nexlizet. Succ

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 17:10
Source
AD HOC NEWS
Quartr Direct company coverage

Esperion Therapeutics (ESPR) AGM 2026 Summary

Esperion Therapeutics held its 2026 AGM, marking the CEO's sixth year and confirming a quorum with over 257 million shares. Two Class I directors were nominated for re-election, and shareholders approved all four proposals, including the election of directors, executive compensat

Tone
Positive 64/100
Event
Market update
Published
07 Jul 2026 14:39
Source
Quartr
Moomoo Direct company coverage

Esperion Therapeutics (ESPR) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Esperion Therapeutics (ESPR). It includes detailed financial analysis, price targets from various analysts, and a summary of recent performance and market sentiment for the company.

Tone
Neutral 50/100
Event
Guidance
Published
05 Jul 2026 02:10
Source
Moomoo
Finviz Direct company coverage

ESPR - Esperion Therapeutics Inc Volatility & Greeks

This article provides a detailed financial overview of Esperion Therapeutics Inc (ESPR), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, short interest, and volatility metrics,

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 14:10
Source
Finviz
Ad-hoc-news.de Direct company coverage

Esperion Therapeutics focuses on cholesterol treatments as investors watch long-term growth

Esperion Therapeutics, a biopharmaceutical company, centers its strategy on developing oral non-statin cholesterol therapies for patients who cannot tolerate statins or need additional lipid-lowering support. The company aims to differentiate itself by offering an oral alternativ

Tone
Positive 70/100
Event
Market update
Published
03 Jul 2026 11:21
Source
Ad-hoc-news.de
TradingView Direct company coverage

Enterprise value to revenue forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR

This article provides financial information for Esperion Therapeutics, Inc. (ESPR) on TradingView, focusing on its enterprise value to forward revenue. It highlights the company's stock market presence on Nasdaq within the pharmaceuticals sector, offering an overview of its finan

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:39
Source
TradingView